Haemonetics (HAE) Accumulated Expenses (2010 - 2026)

Haemonetics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $68.2 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 14.76% year-over-year to $68.2 million in Q1 2026; TTM through Mar 2026 was $68.2 million, a 14.76% increase from a year earlier, with the FY2026 full-year figure at $68.2 million, up 14.76% from the prior year.
• Accumulated Expenses improved to $68.2 million in Q1 2026 per HAE's latest filing, from $52.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $80.7 million in Q1 2024 and bottomed at $30.4 million in Q3 2022.
• The 5-year median for Accumulated Expenses is $48.4 million (2022), against an average of $49.8 million.
• Across the five-year window, Accumulated Expenses soared 33.64% in 2022 and decreased 26.37% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $52.2 million in 2022, then advanced by 12.61% to $58.8 million in 2023, then decreased by 21.83% to $45.9 million in 2024, then rose by 13.42% to $52.1 million in 2025, then jumped by 30.89% to $68.2 million in 2026.
• Per Business Quant, the three latest HAE Accumulated Expenses figures stand at $68.2 million (Q1 2026), $52.1 million (Q4 2025), and $48.3 million (Q3 2025).